Form 4: Adaptive Biotechnologies CEO Chad Robins Reports Stock Transactions

Chad Robins, CEO and Chairman of Adaptive Biotechnologies, reports the acquisition and disposal of company stock to cover tax obligations related to RSU vesting.

Summary

• On March 4, 2024, Chad Robins acquired 354,610 shares of Adaptive Biotechnologies common stock at $0.
• Following this acquisition, Robins directly owned 2,625,374 shares.
• On March 5, 2024, Robins sold 5,879 shares at $3.44 and 42,794 shares at $3.43.
• These sales resulted in Robins directly owning 2,619,495 and then 2,576,701 shares respectively.
• The transactions were to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are related to tax obligations and don't necessarily reflect a change in the executive's confidence in the company.

Positives

• The acquisition of shares, even if immediately followed by a sale, indicates continued alignment with the company's success.

Negatives

• The sale of shares, even if for tax obligations, could be perceived negatively by some investors.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term price volatility.

Management Comments

• The sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

Insider transactions are common and closely monitored in the biotechnology industry, especially those related to equity compensation.

Comparison to Industry Standards

• Sell-to-cover transactions are a standard practice in many publicly traded companies, including those in the biotechnology sector, to manage tax obligations related to equity compensation.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar mechanisms for their employees' RSU vesting.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the small volume of shares sold.

Key Dates